טוען...
Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women
BACKGROUND: Tamoxifen can reduce the risk of developing invasive estrogen-receptor positive (ER+) breast cancer by 49%, but it is unknown how many women in the U.S. are taking tamoxifen for primary prevention of breast cancer. METHODS: Data from the years 2000 and 2005 National Health Interview Surv...
שמור ב:
| Main Authors: | , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3038785/ https://ncbi.nlm.nih.gov/pubmed/20142242 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1055-9965.EPI-09-0930 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|